• Vaccine Name: Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine
• Target Pathogen: Actinobacillus pleuropneumoniae
• Target Disease: porcine pleuropneumonia
• Type: Live, attenuated vaccine
• Status: Research
• ApxIIC gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• ApxIVA gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: Plasmid pENT1 was used to introduce the ΔapxIVA deletion into A. pleuropneumoniae single mutant ΔapxIIC via the single-step transconjugation system. The colonies with the correct PCR profile were confirmed by Southern blot and sequencing assays (Liu et al., 2007).
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Persistence: The LD50 data shown that the double mutant ΔapxIICΔapxIVA was attenuated by three-fold, compared with the single mutant HB04C− (Liu et al., 2007).
• Efficacy: Two weeks after secondary immunization, all mice were challenged with 10 LD50 of homologous (WF83) (6.0 × 107) and heterologous (1.8 × 106) (S4074) virulent A. pleuropneumonaie by intraperitoneal route. There was no mouse died in groups 1 and 2, which shown a protection efficiency of 100% against homologous challenge (Liu et al., 2007).